Bioventures 2018 L.P. Mpm Sells 29,088 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Posted by George Bondi on Sep 5th, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 29,088 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $7.06, for a total value of $205,361.28. Following the sale, the insider directly owned 4,202,346 shares in the company, valued at approximately $29,668,562.76. This represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total transaction of $231,325.71.
On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.19, for a total transaction of $180,691.89.
On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $26,168.33.
On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Performance

Entrada Therapeutics stock opened at $7.13 on Friday. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The firm’s 50-day moving average is $7.06 and its 200-day moving average is $9.19. The company has a market cap of $277.64 million, a P/E ratio of -1.80 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, sell-side analysts predict that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Alliancebernstein L.P. increased its stake in shares of Entrada Therapeutics by 7.1% in the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after purchasing an additional 1,620 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Entrada Therapeutics by 11.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 19,465 shares of the company’s stock worth $246,000 after buying an additional 1,970 shares during the period. Great Lakes Advisors LLC boosted its position in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after buying an additional 2,239 shares during the period. Quadrature Capital Ltd boosted its position in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after buying an additional 2,424 shares during the period. Finally, First Trust Advisors LP grew its holdings in Entrada Therapeutics by 3.6% in the 2nd quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock worth $505,000 after buying an additional 2,631 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several recent research reports. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Finally, Guggenheim dropped their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Get Our Latest Research Report on Entrada Therapeutics

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.